학술논문

COVID-19 in Renal Transplant Recipients -- A Single Center Experience from India.
Document Type
Article
Source
Indian Journal of Nephrology. Sep/Oct2022, Vol. 32 Issue 5, p416-422. 7p.
Subject
*CHRONIC kidney failure
*EVALUATION of medical care
*INTENSIVE care units
*COVID-19
*FEVER
*CHEST X rays
*TIME
*IMMUNOCOMPROMISED patients
*KIDNEY transplantation
*PATIENTS
*RETROSPECTIVE studies
*DISEASE incidence
*DYSPNEA
*ARTIFICIAL respiration
*SEVERITY of illness index
*LYMPHOPENIA
*HOSPITAL care
*CRITICAL care medicine
*SYMPTOMS
*DESCRIPTIVE statistics
*COUGH
*BLOOD testing
*COMPUTED tomography
*HEMODIALYSIS
*TRANSPLANTATION of organs, tissues, etc.
*LONGITUDINAL method
*ACUTE kidney failure
Language
ISSN
0971-4065
Abstract
Introduction: The information on the clinical outcome of renal transplant recipients getting COVID-19 infection is sparse. The aim of this study is to report a single-center experience of renal transplant recipients with COVID-19 from India. Methods: This was a retrospective study of 23 consecutive renal transplant recipients with COVID-19 infection presenting to our center from May 2020 to August 2020. Clinical parameters, laboratory values, imaging characteristics, and outcome of the patients were collected and analyzed. Results: Median follow-up duration was 36 (range: 10--110) days. Median age of patients was 54 (23--70) years, and 87% were male. Median duration since transplant was 69 (range: 15--132) months. The most common presenting feature was fever (82.6%), followed by breathlessness (43.5%) and cough (30.4%). Hospitalization rate was 52.2%, while 34.8% required ICU care. Severe to critical disease was seen in 39.1% of patients, and 17.4% required mechanical ventilation. Patients with severe disease had a higher incidence of lymphopenia (P = 0.005) when compared to the ones with mild to moderate disease. Acute kidney injury was seen in 39.1% of patients, and 13% required dialysis. Mortality rate was 13% overall, and 25% in those hospitalized. Conclusion: Renal transplant recipients with COVID-19 have a poor outcome. Although not all of them need hospitalization, they should be monitored closely. Immunosuppression minimization is an important part of the treatment strategy. [ABSTRACT FROM AUTHOR]